Dewan Md Sakib Hossain
Overview
Explore the profile of Dewan Md Sakib Hossain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1098
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo
Zhang Q, Sakib Hossain D, Nechaev S, Kozlowska A, Zhang W, Liu Y, et al.
Blood
. 2013 Jan;
121(8):1304-15.
PMID: 23287859
STAT3 operates in both cancer cells and tumor-associated immune cells to promote cancer progression. As a transcription factor, it is a highly desirable but difficult target for pharmacologic inhibition. We...
12.
Sakib Hossain D, Mohanty S, Ray P, Das T, Sa G
Front Biosci (Schol Ed)
. 2011 Dec;
4(2):502-19.
PMID: 22202073
Despite major advances in understanding the mechanisms of tumor immunity, its successful translation into effective tumor immunotherapy is hindered by the ability of tumors to foster a tolerant microenvironment and...
13.
Sakib Hossain D, Bhattacharyya S, Das T, Sa G
Front Biosci (Schol Ed)
. 2011 Dec;
4(1):335-55.
PMID: 22202064
Tumors are multifaceted; in fact, numerous things happen in synchrony to enable tumor promotion and progression. Any type of cancer is associated with the modification of 300-500 normal genes and...
14.
Sen G, Mohanty S, Sakib Hossain D, Bhattacharyya S, Banerjee S, Chakraborty J, et al.
J Biol Chem
. 2011 Oct;
286(49):42232-42247.
PMID: 22013068
Breast cancer cells often develop multiple mechanisms of drug resistance during tumor progression, which is the major reason for the failure of breast cancer therapy. High constitutive activation of NFκB...
15.
Chakraborty J, Banerjee S, Ray P, Sakib Hossain D, Bhattacharyya S, Adhikary A, et al.
J Biol Chem
. 2010 Aug;
285(43):33104-33112.
PMID: 20675383
Tumor suppressor p53 plays the central role in regulating apoptosis in response to genotoxic stress. From an evolutionary perspective, the activity of p53 has to be backed up by other...
16.
Bhattacharyya S, Sakib Hossain D, Mohanty S, Sen G, Chattopadhyay S, Banerjee S, et al.
Cell Mol Immunol
. 2010 Mar;
7(4):306-15.
PMID: 20305684
Immune dysfunction is well documented during tumor progression and likely contributes to tumor immune evasion. CD8(+) cytotoxic T lymphocytes (CTLs) are involved in antigen-specific tumor destruction and CD4(+) T cells...
17.
Lahiry L, Saha B, Chakraborty J, Adhikary A, Mohanty S, Sakib Hossain D, et al.
Carcinogenesis
. 2009 Dec;
31(2):259-68.
PMID: 19969555
The most common alterations found in breast cancer are inactivation or mutation of tumor suppressor gene p53. The present study revealed that theaflavins induced p53-mutated human breast cancer cell apoptosis....
18.
Theaflavins retard human breast cancer cell migration by inhibiting NF-kappaB via p53-ROS cross-talk
Adhikary A, Mohanty S, Lahiry L, Sakib Hossain D, Chakraborty S, Das T
FEBS Lett
. 2009 Nov;
584(1):7-14.
PMID: 19883646
The present study demonstrates that theaflavins exploit p53 to impede metastasis in human breast cancer cells. Our data suggest that p53-dependent reactive oxygen species (ROS) induce p53-phosphorylation via p38MAPK in...
19.
Chattopadhyay S, Bhattacharyya S, Saha B, Chakraborty J, Mohanty S, Sakib Hossain D, et al.
PLoS One
. 2009 Oct;
4(10):e7382.
PMID: 19812686
Background: Many tumors are associated with decreased cellular immunity and elevated levels of prostaglandin E2 (PGE2), a known inhibitor of CD4+ T cell activation and inducer of type-2 cytokine bias....